RxDoctor Payments Data

Jonathan Mines, MD

Retina Specialist · Riverview, FLNPI 1366405326

Payments from drug & device makers

$2,986in general payments, 2019–2025

Across 33 payments — averaging $90.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$593
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$284
  • Apellis Pharmaceuticals, Inc.$280
  • AbbVie$270
  • Sight Sciences, Inc.$249
  • Sun Pharmaceutical Industries Inc.$240
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$2,986100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,986 in reported general payments places this provider in the 40th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$499,520
Medicare patients
421
Services billed
4,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept124$252,485
SyfovrePegcetacoplan/Pf95$247,360
VabysmoFaricimab-Svoa84$206,278
OzurdexDexamethasone57$104,887
Eylea HdAflibercept16$39,490
LucentisRanibizumab14$33,255
Alphagan PBrimonidine Tartrate14$4,541
Prednisolone Acetate118$3,905
Brimonidine Tartrate13$1,824
Atropine Sulfate65$1,802
Tobramycin98$492
Latanoprost21$237
Timolol Maleate34$215
ErythromycinErythromycin Base11$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd$593$291,975140 claims
Apellis Pharmaceuticals, Inc.Syfovre$280$247,36095 claims
Genentech USA, Inc.Vabysmo$124$206,27884 claims
AbbVieOzurdex, Alphagan P$270$109,42871 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 118 retina specialist providers in Florida.

Other retina specialist in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →